<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007276</url>
  </required_header>
  <id_info>
    <org_study_id>Lumify Study</org_study_id>
    <nct_id>NCT04007276</nct_id>
  </id_info>
  <brief_title>The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients</brief_title>
  <official_title>The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead
      to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure
      while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution
      0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of
      glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye
      redness, intraocular pressure, and eyelid position in patients with glaucoma who are already
      using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each patient will be randomized to receive the study medication in one eye and placebo in the other eye.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular redness</measure>
    <time_frame>5 minutes after application of eye drop</time_frame>
    <description>Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular redness</measure>
    <time_frame>15 minutes after application of eye drop</time_frame>
    <description>Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular redness</measure>
    <time_frame>30 minutes after application of eye drop</time_frame>
    <description>Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular redness</measure>
    <time_frame>60 minutes after application of eye drop</time_frame>
    <description>Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>60 minutes after application of eye drop</time_frame>
    <description>Measurement of intraocular pressure using handheld tonometer (TonoPen)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Palpebral fissure height</measure>
    <time_frame>60 minutes after application of eye drop</time_frame>
    <description>Measurement of distance between inner margin of upper and lower eyelids from clinical photographs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye discomfort</measure>
    <time_frame>60 minutes after application of eye drop</time_frame>
    <description>Subjective scoring of ocular discomfort by patient on a 0-10 unit scale (0 = very comfortable, 10 = very uncomfortable)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Glaucoma</condition>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Glaucoma; Drugs</condition>
  <condition>Droopy Eyelid</condition>
  <condition>Ptosis</condition>
  <condition>Glaucoma, Primary Open Angle</condition>
  <arm_group>
    <arm_group_label>Lumify Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>In each subject, each eye will be randomized to receive a single drop of either Lumify™ (brimonidine tartrate ophthalmic solution 0.025%) or a sterile balanced saline solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brimonidine tartrate ophthalmic solution 0.025%</intervention_name>
    <description>Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.</description>
    <arm_group_label>Lumify Arm</arm_group_label>
    <other_name>Lumify™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sterile balanced saline solution</intervention_name>
    <description>Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Diagnosis of primary open angle glaucoma

          -  Willing and able to give informed consent

          -  Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use

        Exclusion Criteria:

          -  Pregnancy

          -  Prisoners

          -  Known allergy or sensitivities to brimonidine

          -  No surgery within the past 6 months

          -  No history of lid surgery or botox

          -  Any other significant ophthalmologic disorder or condition with relevant effect on
             ocular redness, IOP, or eyelid position as evaluated by principal investigator

          -  Inability to sit comfortably for 30 minutes

          -  Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or
             phenylephrine dilating drops within 1 week of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ze Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ze Zhang, MD</last_name>
    <phone>504-988-5831</phone>
    <email>zzhang9@tulane.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacquelyn Laplant, MD</last_name>
    <phone>610-247-6207</phone>
    <email>jlaplant@tulane.edu</email>
  </overall_contact_backup>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tulane University</investigator_affiliation>
    <investigator_full_name>Ze Zhang</investigator_full_name>
    <investigator_title>Principal Investigator, Assistant Professor, Director of Glaucoma Service</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

